DNA damage response, HRR
icon-oncology
Oncology

Harness the power of HRR

BRCA1/2 and beyond

The impairment in the DNA damage repair (DDR) genes is implicated in many cancers including breast, ovarian, prostate and pancreatic. Assessing the DDR status by expanding the biomarker profiling in the homologous recombination repair (HRR) pathway beyond BRCA1/2 is of significance for targeted therapy. Advances in NGS allow us to characterize biomarkers. However, operational bottlenecks such as resources, sample size, workflow optimization, data analysis and reporting still exist and can often hinder progress. Our QIAseq HRR Panel overcome such challenges and provide actionable biomarker insights with fewer resources.
QIAseq Multimodal BRCA, female scientist working on a computer
Detect variants with confidence

The HRR pathway is a high-fidelity pathway that repairs double-strand breaks (DSB)1,2. Many genes, including BRCA1 and BRCA2 are tumor suppressor genes identified as significant mediators of the HRR pathway. Loss or impairment of these genes is associated with many cancers including breast, ovarian, prostate and pancreatic. Detect the pathogenic variants in the HRR pathway with confidence.

Expand your HRR biomarker insights

Use our QIAseq HRR Panel to expand your biomarker coverage. The panel provides streamlined workflow, robust sensitivity with a low sample input across all 15 genes that were part of the PROfound study3.

Interested in a custom panel? We can customize panels with the genes of your interest or add it to the 15 genes we offer.

Customize the panel by adding the genes you want to the 15 genes standard panel
Learn about our DDR solutions
Explore QIAseq HRR panels to confidently assess DDR biomarkers.

Key benefits of QIAseq HRR Panel

Maximize gene coverage, uniformity and precision
Want valuable information on biomarkers within the HRR pathway?
Learn how Dr. Nils Hartmann's lab successfully implemented a streamlined NGS Sample to Insight workflow to identify genetic mutations in multiple HR deficient cancers.
Sample to Insight NGS workflow with QIAseq HRR Panel

Maximize insights with fewer resources

The complete Sample to Insight workflow begins with DNA extraction, followed by library construction and target enrichment with QIAseq HRR Panels. Following NGS, data analysis is performed using the QIAGEN CLC Genomics Workbench. Detected variants can be interpreted with QIAGEN Clinical Insight (QCI) for QIAseq. Detect deficiencies in HRR by assessing variants in 15 HRR pathway genes including BRCA1 and BRCA2 using a streamlined workflow with fewer resources and less sample input.

References
  1. Hirsch, S., Gieldon, L. Sutter, C., Dikow, N., Schaaf, C. (2021) Germline testing for homologous recombination repair genes-opportunities and challenges. Gene Chromosomes Cancer, 60(5), 332-343
  2. Hakem, R. (2008) DNA-damage repair; the good, the bad, and the ugly. The EMBO Journal, 27, 589–605.
  3. clinicaltrials.gov/ct2/show/NCT02987543 Accessed September 28 2020
  4. Turner, N., Tutt, A., Ashworth, A. (2004) Hallmarks of BRCAness in sporadic cancers. Nature Review Cancer, 4, 814–819


The products mentioned here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.